Waltham, Massachusetts-based Alere, Inc. recently announced that its Chief Financial Officer David A. Tietel will leave his position with the INRatio maker. Tietel’s departure comes at a challenging period for the medical device maker. In 2014, Alere recalled its INRatio home PT/INR monitor system and test strips after the medical device was linked with numerous injuries and at least three deaths.
The INRatio and INRatio2 monitor system is used to test an individual’s INR level when taking the blood-thinning drug warfarin. According to the urgent FDA recall issued for the Alere INRatio, the device provided users with erroneously-low INR readings. This malfunction caused users to believe their INR levels were within a safe, therapeutic range when in fact, the users could be at risk for a serious bleeding event or even death.
The medical diagnostics products maker has not hired a replacement for Mr. Teitel, who received $540,779 in compensation during 2013 according to public filings. Mr. Teitel will remain as Alere’s CFO until a replacement is retained.
The Cochran Firm, D.C. is investigating claims related to Alere INRatio bleeding events. If you or someone you love suffered a serious bleeding event after receiving an erroneously-low INR reading from an INRatio monitor, please contact our team of legal professionals at 202-682-5800 during business hours or 1-800-THE-FIRM (843-3476) 24 hours a day. You can also fill out a contact form in order to receive a free, prompt, and confidential case review.
We represent Alere INRatio clients on a contingency basis, meaning you pay nothing unless you are already receiving compensation for your claim. Because the law mandates strict deadlines for filing an INRatio injury claim, we recommend contacting us at your earliest convenience.